Alzheimer’s Groups Seek Broad Medicare Coverage for Pricey Drugs

Industry-backed Alzheimer’s advocacy groups are seeking to rally lawmakers and political candidates around their push for Medicare to broaden coverage for Biogen’s expensive drug Aduhelm and others like it.

The Centers for Medicare & Medicaid Services on Thursday said it would increase coverage for patients taking Leqembi, or lecanemab, from Biogen Inc. and Eisai Co., if the Food and Drug Administration grants the product traditional approval.

The FDA is set to decide on Leqembi by July 6. A traditional approval would prompt the CMS to allow for coverage for patients enrolled in a registry that collects real-world information on ...